Clinical Trial Update: Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Rebif New Formulation (RNF) for relapsing forms of multiple sclerosis has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Rebif New Formulation (RNF) (interferon beta-1a)

Snippet

Sponsor: EMD Serono | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2010-07-09